Sirona Biochem (Sirona Biochem) Debt-to-Equity : -0.84 (As of Jan. 2024)

View and export this data going back to 2009. Start your Free Trial

What is Sirona Biochem Debt-to-Equity?

Sirona Biochem's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jan. 2024 was $0.59 Mil. Sirona Biochem's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jan. 2024 was $1.16 Mil. Sirona Biochem's Total Stockholders Equity for the quarter that ended in Jan. 2024 was $-2.08 Mil. Sirona Biochem's debt to equity for the quarter that ended in Jan. 2024 was -0.84.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Sirona Biochem's Debt-to-Equity or its related term are showing as below:

SRBCF' s Debt-to-Equity Range Over the Past 10 Years
Min: -15.69 Med: 0.32 Max: 26.4
Current: -0.84

During the past 13 years, the highest Debt-to-Equity Ratio of Sirona Biochem was 26.40. The lowest was -15.69. And the median was 0.32.

SRBCF's Debt-to-Equity is not ranked
in the Biotechnology industry.
Industry Median: 0.14 vs SRBCF: -0.84

Sirona Biochem Debt-to-Equity Historical Data

The historical data trend for Sirona Biochem's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sirona Biochem Debt-to-Equity Chart

Sirona Biochem Annual Data

Trend

Oct14

Oct15

Oct16

Oct17

Oct18

Oct19

Oct20

Oct21

Oct22

Oct23

Debt-to-Equity

Get a 7-Day Free Trial

0.71

26.08

-8.78

2.19

-0.87

Sirona Biochem Quarterly Data
	Apr19	Jul19	Oct19	Jan20	Apr20	Jul20	Oct20	Jan21	Apr21	Jul21	Oct21	Jan22	Apr22	Jul22	Oct22	Jan23	Apr23	Jul23	Oct23	Jan24
Debt-to-Equity	Get a 7-Day Free Trial															-1.16	-1.90	-1.25	-0.87	-0.84

Competitive Comparison of Sirona Biochem's Debt-to-Equity

For the Biotechnology subindustry, Sirona Biochem's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Sirona Biochem's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sirona Biochem's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Sirona Biochem's Debt-to-Equity falls into.

Sirona Biochem Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Sirona Biochem's Debt to Equity Ratio for the fiscal year that ended in Oct. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.47	+	1.122)	/	-1.831
	=	-0.87

Sirona Biochem's Debt to Equity Ratio for the quarter that ended in Jan. 2024 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.589	+	1.159)	/	-2.08
	=	-0.84

Sirona Biochem (OTCPK:SRBCF) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Sirona Biochem Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Sirona Biochem's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Sirona Biochem (Sirona Biochem) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sirona Biochem Corp (OTCPK:SRBCF) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

ZSB:Germany SBM:Canada

Address

C/o WeWork, 595 Burrard Street, Vancouver, BC, CAN, V7X 1L3

Website

https://www.sironabiochem.com

Sirona Biochem Corp is a development stage biotechnology company. The principal activities of the company are the development of cosmetic and pharmaceutical active ingredients which are licensed to partners in exchange for upfront, milestone, and royalty payments. The company acts as a cosmetic ingredient and drug discovery company with a proprietary technology platform with a specialization in the stabilization of carbohydrate molecules. It has a business presence in Canada and France.